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Abstract 
Objective: Outcomes used in alcohol brief intervention (ABI) trials vary considerably. 
Achieving consensus about key outcomes can enhance evidence synthesis and improve 
healthcare guidelines. This was an international, e-Delphi study to prioritize outcomes for 
ABI trials as one step in a larger effort to develop an ABI core outcome set (COS). 
Method:  150 registrants from 19 countries, and representing researchers, policymakers, and 
patients, participated in a two-round e-Delphi study. In Round 1, participants (n=137) rated 
86 outcomes, derived from a review of the literature and a patient and public involvement 
panel, by importance. In Round 2, participants (n=114) received feedback on importance 
ratings for each outcome and a reminder of their personal rating before rating the outcomes 
for importance a second time. Seven additional outcomes suggested in Round 1 were added 
to the Round 2 questionnaire. We defined consensus a priori as 70% agreement across all 
stakeholder groups.  
Results: Seven consumption outcomes met inclusion criteria: typical frequency, typical 
quantity, frequency of heavy drinking, alcohol-related problems, and weekly drinks, at risk 
drinking, and combined consumption measures. Others meeting the threshold were: alcohol-
related injury; quality of life; readiness to change; and intervention fidelity. 
Conclusions: This is the first international e-Delphi study to identify and prioritize outcomes 
for use in ABI trials. The use and reporting of outcomes in future ABI trials should improve 
evidence synthesis in systematic reviews and meta-analyses. Further work is required to 
refine these outcomes into a COS that includes guidance for measurement of outcomes. 
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Introduction  
Alcohol brief interventions (ABIs) have emerged as the main approach to addressing 
hazardous and harmful alcohol use in a range of settings, including primary care, emergency 
departments, hospitals, online, criminal justice, workplaces, probation, and universities. 
According to NICE guidance PH24 (National Institute for Health and Clinical Excellence, 
2010), ABIs are suitable for non-treatment-seeking alcohol users aged 16 or over who are 
currently experiencing, or are at risk of experiencing, problems from their alcohol use. ABIs 
are behavioral and/or motivational interventions designed to help drinkers reduce their 
alcohol consumption. They typically consist of a short, single session of feedback and 
tailored advice (brief advice), or longer, motivationally-based interventions that explore 
motivations for drinking and personal barriers to change (extended BI) (Cunningham et al., 
2017). Essential components of ABI’s are defined here as the assessment of personal alcohol 
use and tailored feedback provided directly to the drinker.   
Systematic reviews of ABI trials do not always agree on the efficacy and 
effectiveness of ABIs to change alcohol use (e.g. Davoren et al., 2016; Kaner et al., 2018; 
Khadjesari et al., 2011; White et al., 2010). There are many possible reasons for this 
disagreement, such as changes in the population being studied over time, changes in baseline 
drinking, variability in ABI content and reporting, and inclusion and exclusion criteria 
variations, among other issues. An avoidable source of disagreement in the literature, 
however, arises from the wide variation in outcomes used and the difficulty in combining 
diverse outcomes in meta-analyses (Cumming, 2013; Kaner, et al., 2018). This can be 
variation in ‘what’ outcome is measured or, for a given outcome, variation in ‘how’ the 
outcome is measured. 
Given the increasing role of systematic reviews and meta-analyses in determining 
health policy and given the potential for outcome heterogeneity to compromise these reviews 
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and analyses, there is a growing effort across a wide range of disciplines and disease 
categories to standardize trial outcomes (Williamson & Clarke, 2012). The importance of 
standardizing trial outcome measurement is recognized by the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT; Chan et al., 2013) and Consolidated 
Standards of Reporting Trials (CONSORT; Moher et al., 2010) statements; both statements 
recommend the use of a well-designed core outcome set (COS). A formal process for 
defining a COS has been established by the Core Outcome Measures in Effectiveness Trials 
(COMET) Initiative (Williamson et al., 2012; Williamson et al., 2017), and numerous studies 
using this process have been undertaken (Gargon et al., 2017). Given the current lack of a 
COS for ABI trials and the increasing importance of ABIs in alcohol policies worldwide, an 
ABI COS is urgently needed.  
The selection and application of a COS is relevant to all ABI stakeholders, including 
beneficiaries of ABIs (service users), practitioners, and policymakers (Williamson et al. 
2012). A COS ensures outcomes meaningful to service users are routinely considered in 
clinical trials and policymakers’ perspectives are reflected in trial outcomes. Without a COS, 
the selection of trial outcomes remains at the sole discretion of the involved researchers 
whose decisions about which outcomes to include may be impacted by implicit biases and 
cause unnecessary heterogeneity in the outcomes used across trials. The systematic review 
which informed this work assessed what outcomes are used and how they were measured in 
all ABI trials since 2000 across all settings. Briefly, in 405 eligible trials (out of 33,134 
studies screened), 2,641 outcomes were reported, measured in approximately 1,560 different 
ways (Shorter et al., under review). As every researcher has the opportunity to select from a 
range of outcomes, better standardization of the minimum requirement to measure change 
will maximize the potential of ABI research to influence decision-making, as it has in other 
research areas such as eczema or rheumatoid arthritis (Boers, 1994; Schmitt et al., 2011). 
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To achieve improved standardization of the outcomes used in ABI trials, the Outcome 
Reporting in Brief Intervention Trials: Alcohol (ORBITAL) project (Shorter et al., 2017) is 
working to establish a COS for ABIs using COMET procedures. Endorsed by the 
International Network on Brief Interventions for Alcohol and Other Drugs (INEBRIA) and 
with oversight by the INEBRIA Research Measurement Standardization Special Interest 
Group (RMS-SIG), ORBITAL undertook three, inter-related efforts to establish an ABI COS 
(Shorter et al, 2017). The first was a comprehensive systematic review to determine what 
outcomes are reported in ABI trials (Shorter et al., under review). The second, and the focus 
of this paper, was an international, multi-perspective e-Delphi consensus study to prioritize 
outcomes for use as a minimum set of reported outcomes in all ABI efficacy and 
effectiveness trials. The third step in the COMET process is to recommend a final set of 
specific measures using criteria recommended by the COnsensus-based Standards for the 
selection of health Measurement INstruments (COSMIN) initiative (Mokkink et al., 2016). 
Although ORBITAL is developing the COS as a minimum data standard for ABI trials, trials 
can use other measures alongside the COS as appropriate. Based on the COMET 
methodology (Williamson et al., 2017), ORBITAL places importance on involving a wide 
range of stakeholders in the development of the COS, and in particular the client group 
considered to benefit most from an efficacious or effective intervention. As reported in this 
paper, we used an e-Delphi approach to understand what outcomes are priorities for ABI 
stakeholders in addition to prioritizing outcome domains for use in ABI trials.  
Method 
We conducted an international, multi-stakeholder e-Delphi consensus study by 
generating a list of relevant outcomes which participants were asked to rate in two successive 
rounds. The e-Delphi approach is an iterative consensus technique which presents a series of 
sequential questionnaires asking individuals to rank outcomes in terms of priority for 
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inclusion in a COS for ABI efficacy or effectiveness trials. Ethical approval was granted by 
the School of Health and Social Care Ethics Committee at Teesside University (reference: 
018/17).  
The e-Delphi is an online implementation of the Delphi approach for consensus 
building (Hasson & Keeney, 2011). The e-Delphi approach solicits the opinions of thought-
leaders and experts on a particular topic in successive rounds, with each round providing 
input into the next (Sinha et al., 2011). All Delphi studies use at least two rounds, but some 
use three or more. E-Delphi panelists are informed of the results of prior rounds and allowed 
to revise their opinion based on those results. The goal is to achieve some pre-defined 
threshold of consensus. Key to the e-Delphi approach is the anonymity of panelists. By 
ensuring panel members remain anonymous throughout the process, panelists are free to 
revise their opinion without fear of reputational harm or to refuse to revise their opinion 
without pressure from the group to do so (Hasson, Keeney & McKenna, 2000).  
Participants 
There are no accepted guidelines for panel size to achieve stable consensus in an e-
Delphi study. As such, we were guided by practicality, scope, and time available (Blackwood 
et al., 2015). Consistent with the purposive or criterion sampling approach used by many 
Delphi studies (Hasson et al, 2000), our sampling strategy focused on identifying electronic 
forums used by the relevant stakeholders and then allowing the sample to evolve organically 
as stakeholders shared the invitation to participate. Our sampling approach is best described 
as a purposive, snow-ball sampling approach. Participants were recruited in the following 
ways: emails to relevant mailing lists of researchers, practitioners, and policy-makers in the 
field, such as the INEBRIA google group; emails to corresponding authors of ABI trials 
identified by the systematic review; a tweet circulated on the @teamalphatees at Teesside 
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University; and emails forwarded by recruited participants to additional contacts with 
relevant expertise.  
Participants were recruited between July 4th and August 1st 2017. Those recruited 
included trial investigators, INEBRIA RMS-SIG members, executive leadership of scientific 
organizations, Cochrane Review Group on Drugs and Alcohol members, NICE alcohol use 
disorder prevention PH24 membership group, trialists, statisticians, COS developers, service 
users/patient and public representatives, practitioners, groups involved in developing ABI 
clinical guidance, funders, and research ethics committee members (Shorter et al., 2017). 
Participants often held multiple roles. Consistent with COMET methodology, we included 
researchers, policymakers, and service users/patients in our sample of experts to ensure a 
broad representation of opinions. The patient perspective is particularly important to the 
COMET methodology since user input into this kind of study adds the lived experience of the 
alcohol consumer. Outcomes perceived to be relevant by stakeholders further removed from 
the user experience can appear less relevant to users (Henihan et al., 2015; Henihan et al., 
2016). Also, users can suggest outcomes not immediately apparent as important to 
researchers. Recruitment text and round instructions are available from the corresponding 
author. To minimize attrition, recruitment text stressed the importance of completing both 
rounds. 
Given the organic and evolving nature of our recruitment procedure, it is impossible 
to say how many individuals received an invitation to participate during the window of 
recruitment. For example, the INEBRIA Google group has 653 members, but not all 
members actively monitor the group. Among those members that do monitor the group, we 
cannot determine, nor could we have monitored, how many members forwarded the 
invitation to colleagues. Similarly, we have no way of tracking how many of the 458 
@teamalphatees twitter followers saw the e-Delphi invitation. Furthermore, the anonymous 
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nature of the e-Delphi made it impossible to track the acceptance rate of the approximately 
250 invitation emails we sent in any systematic way. Thus, we cannot provide a response rate 
in a traditional sense. The relevance of a traditional response rate is unclear, however, given 
the purposive, anonymous, snow-ball sampling approach we used. Therefore, rather than 
focus on a response rate per se, we monitored the number of panelists in each of the three 
basic stakeholder types: researcher, policymaker, and patient. We did not attempt to 
“balance” the participants across types but rather tried to ensure a sufficient number of each 
type.  
The Delphi questionnaire and rounds 
The e-Delphi used a bespoke online e-management system ‘DelphiManager’, 
maintained by the COMET initiative to facilitate core outcome set development. In both 
rounds, participants scored each outcome using the Grading of Recommendations 
Assessment, Development, and Evaluations (GRADE) scale of 1-9, with 1–3 labelled ‘not 
important for inclusion’, 4–6 labelled ‘important but not critical’ and 7–9 labelled ‘critical for 
inclusion’ (Guyatt et al., 2011). Outcomes were derived from the first 100 papers in a 
systematic review of existing ABI effectiveness and efficacy trials (Shorter et al, under 
review; Registered at PROSPERO, CRD42016047185; Shorter et al., 2016). These papers 
were not randomly selected but did represent a range of ABI settings and the full spectrum of 
years from 2000-2016. Current or former hazardous drinkers (n=9) formed a patient and 
public involvement panel, some from an established service user representative group 
(Belfast Experts by Experience), and others known to the lead author as drinking hazardously 
or above (and not researchers, clinicians, or members of other professional groups related to 
drinking or other addictive behaviors). The hazardous drinking individuals on this panel 
(n=5) were recruited through personal invitation from the lead author, and were verified as 
hazardous drinkers by an AUDIT score of eight or more. The patient and public involvement 
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panel added additional outcomes to the questionnaire at Round 1. Every outcome was given a 
descriptor. The outcomes were discussed and refined for clarity by the patient and public 
involvement panel and the authors.  
In Round 1, there were 86 outcomes presented to participants. Participants could add 
additional outcomes and comment on the reason for their outcome ranking. Suggested 
outcomes from Round 1 were reviewed and coded to determine their novelty (i.e. that they 
were not covered by existing outcomes in the questionnaire). The additional outcomes and 
decisions made can be seen in supplementary material A. Round 2 included the 86 original 
outcomes, the seven additional outcomes, the individual’s personal ranking, and rankings 
grouped by stakeholder group (researchers, healthcare and other professionals, and service 
users/representatives). Round 1 and Round 2 both used the same GRADE ranking system. 
All those who registered in Round 1 were invited to take part, with Round 2 closing on 
September 12th 2017. Consensus was defined a priori (Shorter, et al., 2017) as 70% or more 
of the respondents scoring an outcome from seven to nine and fewer than 15% scoring it one 
to three (Blackwood et al., 2015; Eleftheriadou et al., 2015). This would illustrate an outcome 
agreed critically important by the majority and little or no importance by a small minority 
(Shorter, et al., 2017). Although there is no formal guidance for the reporting of e-Delphi 
studies, we followed recommendations by Sinha et al. (2011). Participants received no 
financial incentive to participate.  
Results  
There were 150 total registrants. Overall, 137 took part in at least one question in 
Round 1 (including five partial completions) and 114 took part in at least one question in 
Round 2 (including 10 partial completions) – referred to as participants. In total, 107 took 
part in at least one question in both rounds, 30 completed Round 1 only, seven completed 
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Round 2 only, and seven registered but did not complete either round. A single person’s 
response contributed between 1.1%- 0.7% (Round 1), and 1.4%- 0.9% (Round 2) to a 
percentage total (variability range includes missing data or ‘prefer not to answer’). As noted 
in a recent systematic review (Boulkedid et al., 2011), few Delphi studies report response 
rates for all rounds, so it is difficult to determine if our rate of attrition from Round 1 to 
Round 2 is typical. This same review found the median number of invited participants in 
Delphi studies was only 17. Thus, we conclude that our sample size is more than sufficient 
and since our sample is intentionally purposive, not representative, we also conclude that any 
attrition from Round 1 to Round 2 is not problematic. 
Details of participants/registrants are given in Table 1. The largest proportions of 
respondents were researchers, female, and from the UK or USA. Because ABI “patients” are 
most often hazardous drinkers who are not treatment seeking, and often do not consider 
themselves to be alcohol patients, this group was the most problematic to identify and recruit, 
and consequently had the lowest representation across participant types. In total, participants 
were from 19 countries (several noted ‘other’ but without stating country name). The 
majority had been involved in at least one ABI trial (70.7%) and around a quarter had been 
involved in four or more. Most participants had no experience of reviews of ABIs or of 
developing measurement instruments (59.3% and 60.7% respectively). In addition, the 
majority had no experience with core outcome set development (71.3%). Of those with 
previous experience, most had been involved in developing one core outcome set. The 
majority of ABI trial experience was in a healthcare setting: 38.0% had experience in alcohol 
or drug treatment settings; 36.7% in primary care; outpatient and inpatient care both had 
33.3% each; and 31.3% in emergency care settings. 
The ranking of consumption measures is given in Table 2. Based on Round 1 ranking, 
four met the 70% threshold. On review by participants in Round 2, seven met this criterion. 
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These were: typical frequency; frequency of heavy drinking; number of drinks in a week; 
hazardous or harmful drinking; alcohol-related problems; combined consumption measure; 
and typical quantity. There was least change in views on alcohol-related problems, with an 
increase of 0.8% in those ranking this outcome ‘critical for inclusion’ between rounds. By 
contrast, the largest increase in those ranking ‘critical for inclusion’ was in the typical 
quantity outcome which increased by 15%. 
Rankings of the remaining domains are given in Table 3. Biomarkers were typically 
under-ranked, with a higher proportion selecting ‘unable to score’ than in any other domain. 
However, of those that were ranked, the highest ranked were levels of Phosphatidylethanol 
and Alanine aminotransferase, but none met either threshold for scores in the ‘critical for 
inclusion’ range or ‘not important for inclusion’ range. In the resource use and economic 
factors domain, none met the 70% threshold for those in the ‘critical for inclusion’ range. 
However, four met the lowered 60% threshold. These were: alcohol-related injury; use; 
alcohol or drug treatment; emergency healthcare; and hospitalization. In the life impact 
domain, the highest ranked outcome was quality of life. This outcome was ranked 79.4% in 
the ‘critical for inclusion’ range at the end of Round 2, reflecting an increase of 16% from the 
corresponding range in round 1. Only one of the health domain outcomes met the lowered 
criterion of 60% in the ‘critical for inclusion’ range: psychological or mental health (64.7% in 
the ‘critical for inclusion’ range at Round 2). Only one item from the psychological factors 
domain met the 70% threshold of ‘critical for inclusion’ range. This was ‘interest in making 
changes around alcohol use’. Finally, only one item in the intervention factors domain was 
ranked as ‘critical for inclusion’. This related to whether the intervention was delivered as 
planned. The ranking for this item was 81.4% in the ‘critical for inclusion’ range in Round 2. 
Discussion 
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Given that ABIs are a key component of alcohol policies worldwide, it is vital that 
policy makers, service commissioners, and practitioners are able to access and synthesize 
robust, consistent evidence to inform their implementation (Babor et al., 2007; Bernstein et 
al., 2010). A key factor currently impeding existing evidence synthesis efforts is a lack of 
standardized outcomes used in ABI trials (Shorter, et al., 2017). As seen in other fields, 
standardization of outcomes will improve the ability of others to synthesize and evaluate the 
literature. Thus, the COMET Initiative has developed a formal, multi-phase methodology 
(Williamson et al., 2012; Williamson et al., 2017) that researchers can use to establish a core 
outcome set (COS). 
As part of the larger, multi-phase ORBITAL project endorsed by INEBRIA, this 
study is one step in establishing a COS for ABI trials using the COMET methodology. 
ORBITAL aims to simplify and inform future ABI trial decision-making (Daykin et al., 
2016; Daykin et al., 2017) and move beyond individual trial researcher preference as the 
primary vehicle by which outcomes are chosen to one of consensus between stakeholders 
(Williamson et al., 2017). This study presents the results of the ORBITAL e-Delphi study and 
is the first attempt to seek international, multi-stakeholder perspectives on which outcomes 
should be prioritized for ABI trials.   
The results of our e-Delphi study suggest that considerable standardization of 
outcomes used in the ABI trials is possible. A systematic review conducted as part of the 
larger ORBITAL effort (Shorter et al., under review) found that 2,641 outcomes, measured in 
approximately 1,560 different ways, were reported in ABI trials, suggesting enormous 
variability in the outcomes that the ABI research community prioritize. Yet our e-Delphi 
study found only nine outcomes met our a priori consensus threshold, seven of which were 
related to alcohol consumption. Relaxing our a priori threshold resulted in an additional five 
outcomes, four of which were related to healthcare use. Thus, our e-Delphi study suggests 
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that much of the variation in the outcomes used in the ABI literature is driven by 
idiosyncratic decisions by individual researchers regarding the specific outcomes for any 
given trial rather than by a fundamental diversity of relevant outcome domains. If this 
conclusion is correct, then the ORBITAL effort to develop an ABI COS will greatly improve 
the ability of ABI researchers to provide consistent, policy-relevant evidence across studies 
on the outcomes they view as most important.  
The validity of this conclusion, however, depends on the composition of our e-Delphi 
panel. As recommended by current best practice guidelines, we included a diverse set of 
panelists in our e-Delphi (Blackwood, et al., 2015). Participants were from a range of 
countries (19 countries across six continents) and stakeholder groups (researchers, 
policymakers, and service users/patients) in order to capture a broad range of perspectives. 
Most were from the UK or the USA, however, and participants from South America and Asia 
were under-represented. We must therefore be cautious about the cultural relevance of 
prioritized outcomes in these locations (Hula et al., 2014). Furthermore, most panelists were 
researchers, which may have over-represented the consensus views of ABI researchers 
compared to other vital perspectives such as those of healthcare professionals, policymakers, 
and patient or public representatives. Diverse perspectives are likely to result in wider 
acceptance of the prioritized outcomes deemed critical to include in ABI studies, although we 
note priorities may differ in different participant groups and ABI settings (Hula et al., 2014). 
For example, despite a wide range of critical outcomes identified by the panel, no 
critical outcomes were identified in the biomarkers domain. We can only speculate as to why 
no biomarker measure made it to the critical measure threshold. It may be that biomarker 
measures were less well understood by our online Delphi participants. However, it is also 
important to note they are less commonly reported in ABI trials (Kypri, 2007). This may be 
because biomarkers are generally considered more relevant to dependence, have poor 
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sensitivity and/or specificity, or are inconvenient to use in comparison to self-report (Allen & 
Litten, 2003; Babor et al., 2000). Despite the lack of biomarker measures, our Delphi study 
identified outcomes across six domains, broadening the types of outcomes typically 
considered by any given ABI trial, while at the same time offering the possibility of 
standardizing outcomes across studies. This broadening highlights the importance of 
selecting outcome measures based on a consensus of the field rather than simply relying on 
what has been measured in prior research (Sinha et al., 2011).  
Although our online Delphi study is the most rigorous attempt to identify the 
appropriate outcome measures for ABI trials thus far, it is subject to some limitations. There 
is ambiguity as to what constitutes consensus (Sinha et al., 2011) and so our a priori choice 
of 70% agreement is subject to possible criticism. Although we attempted to balance 
perspectives within our Delphi panel, difficulties in recruiting some participant types, 
particularly policymakers and patients, may have skewed the overall panel recommendations 
towards a researcher perspective. Similarly, the predominance of English-speaking countries 
among our panelists, especially the UK and the USA, may also have influenced our results 
and suggests caution with regard to the generalizability of our findings to non-English 
speaking and to low- or middle-income countries. Finally, given the nature of recruitment 
into our Delphi panel, it is not possible to determine the true response rate to our Round 1 
invitation. This, combined with attrition between Rounds 1 and 2, may limit the validity of 
our results. Our use of anonymous voting and the diverse composition of our panel, however, 
adds to what is known about outcome priorities in the ABI field.  
This study is the first attempt to identify outcomes using consensus methods for 
consideration in a core outcome set in ABI trials. It prioritizes outcomes that are most 
important to a range of key stakeholders in the field and will help guide researchers in 
choosing outcomes in future trials. The items prioritized here will be useful to improve 
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evidence synthesis in future systematic reviews in the field. However, the prioritization of 
these outcomes is a dynamic rather than fixed process. More research is needed to: a) further 
prioritize these outcomes into a core outcome set for all trials of ABIs ; b) replicate this 
priority list over time and in under-represented groups; c) identify the best measures to 
represent these outcomes; and d) to determine if the adoption of these recommended 
outcomes improves standards in the field. The ORBITAL project, with oversight from the 
INEBRIA RMS-SIG, is pursuing these next steps to fulfill its charge of developing a 
consensus-based ABI COS to help drive the future of ABI research.  
  
16 Shorter 
 
 
 
Acknowledgements 
We would like to thank and acknowledge the funding from Alcohol Research UK (Research 
Innovation Grant Number: R2016/04) and the INEBRIA Research Measurement 
Standardization Special Interest Group for feedback and useful commentary at the INEBRIA 
2016 conference workshop on the topic. We are grateful to patient and public representatives 
who gave their views on the proposed work. 
  
17 Shorter 
 
 
 
References 
Allen, J. P., & Litten, R. Z. (2003). Recommendations on Use of Biomarkers in Alcoholism 
Treatment Trials. Alcoholism: Clinical and Experimental Research, 27(10), 1667-
1670. 
Babor, T. F., McRee, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. 
(2007). Screening, Brief Intervention, and Referral to Treatment (SBIRT): toward a 
public health approach to the management of substance abuse. Substance Abuse, 
28(3), 7-30.  
Babor, T. F., Steinberg, K., Anton, R., & Del Boca, F. (2000). Talk is cheap: measuring 
drinking outcomes in clinical trials. Journal of studies on alcohol, 61(1), 55-63.  
Bernstein, J. A., Bernstein, E., & Heeren, T. C. (2010). Mechanisms of change in control 
group drinking in clinical trials of brief alcohol intervention: Implications for bias 
toward the null. Drug and Alcohol Review, 29(5), 498-507.  
Blackwood, B., Ringrow, S., Clarke, M., Marshall, J., Rose, L., Williamson, P., & McAuley, 
D. (2015). Core Outcomes in Ventilation Trials (COVenT): protocol for a core 
outcome set using a Delphi survey with a nested randomised trial and observational 
cohort study. Trials, 16, 368-374.  
Boers, M. (1994). World Health Organization and International League of Associations for 
Rheumatology core endpoints for symptom modifying antirheumatic drugs in 
rheumatoid arthritis clinical trials. J Rheumatol Suppl, 41.  
Boulkedid, R., Abdoul, H., Loustau, M., Sibony, O., & Alberti, C. (2011). Using and 
reporting the Delphi method for selecting healthcare quality indicators: a systematic 
review. PloS one, 6(6), e20476. 
18 Shorter 
 
 
 
Chan, A. W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gotzsche, P. C., Krleza-Jeric, K., . 
. . Moher, D. (2013). SPIRIT 2013 statement: defining standard protocol items for 
clinical trials. Annals of Internal Medicine, 158(3), 200-207. 
Cumming, G. (2013). Understanding the new statistics: Effect sizes, confidence intervals, and 
meta-analysis. New York: Routledge. 
Cunningham, J. A., Shorter, G. W., Murphy, M., Kushnir, V., Rehm, J., & Hendershot, C. S. 
(2017). Randomized Controlled Trial of a Brief Versus Extended Internet Intervention 
for Problem Drinkers. International Journal of Behavioral Medicine, 24, 760-767 
Davoren, M. P., Demant, J., Shiely, F., & Perry, I. J. (2016). Alcohol consumption among 
university students in Ireland and the United Kingdom from 2002 to 2014: a 
systematic review. BMC Public Health, 16, 173. doi:10.1186/s12889-016-2843-1 
Daykin, A., Selman, L. E., Cramer, H., McCann, S., Shorter, G. W., Sydes, M. R., . . . Shaw, 
A. J. T. (2017). ‘We all want to succeed, but we’ve also got to be realistic about what 
is happening’: an ethnographic study of relationships in trial oversight and their 
impact. 18(1), 612. 
Daykin, A., Selman, L. E., Cramer, H., McCann, S., Shorter, G. W., Sydes, M. R., . . . Shaw, 
A. J. T. (2016). What are the roles and valued attributes of a Trial Steering 
Committee? Ethnographic study of eight clinical trials facing challenges. 17(1), 307. 
Eleftheriadou, V., Thomas, K., van Geel, N., Hamzavi, I., Lim, H., Suzuki, T., . . . Vitiligo 
Global Issues Consensus, G. (2015). Developing core outcome set for vitiligo clinical 
trials: international e-Delphi consensus. Pigment Cell Melanoma Res, 28(3), 363-369.  
Gargon, E., Williamson, P. R., Altman, D. G., Blazeby, J. M., Tunis, S., & Clarke, M. (2017). 
The COMET Initiative database: progress and activities update (2015). Trials, 18(1), 
54. 
19 Shorter 
 
 
 
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., . . . Schunemann, H. 
J. (2011). GRADE guidelines: 2. Framing the question and deciding on important 
outcomes. Journal of Clinical Epidemiology, 64(4), 395-400.  
Hasson, F., & Keeney, S. (2011). Enhancing rigour in the Delphi technique research. 
Technological Forecasting and Social Change, 78(9), 1695-1704. 
Hasson, F., Keeney, S., & McKenna, H. (2000). Research guidelines for the Delphi survey 
technique. Journal of advanced nursing, 32(4), 1008-1015. 
Henihan, A. M., Klimas, J., Bury, G., O’Toole, T., Rieckman, T., Shorter, G., & Cullen, W. 
(2015). Methodological challenges and issues of recruiting for mental health and 
substance use disorders trials in primary care. Addiction science & clinical practice, 
10(1), A21.  
Henihan, A. M., McCombe, G., Klimas, J., Swan, D., Leahy, D., Anderson, R., . . . Cullen, 
W. (2016). Feasibility of alcohol screening among patients receiving opioid treatment 
in primary care. BMC Family Practice, 17(1), 153. 
Hula, W. D., Fergadiotis, G., & Doyle, P. J. (2014). A core outcome set for aphasia treatment 
research: Obstacles, risks, and benefits. Aphasiology, 28(11), 1396-1399.  
Kaner, E. F. S., Beyer, F. R., Muirhead, C., Campbell, F., Pienaar, E. D., Bertholet, N., . . . 
Burnand, B. (2018). Effectiveness of brief alcohol interventions in primary care 
populations. Cochrane Database of Systematic Reviews(2), CD004148.  
Khadjesari, Z., Murray, E., Hewitt, C., Hartley, S., & Godfrey, C. (2011). Can stand-alone 
computer-based interventions reduce alcohol consumption? A systematic review. 
Addiction, 106(2), 267-282.  
Kypri, K. (2007). Methodological issues in alcohol screening and brief intervention research. 
Substance Abuse, 28(3), 31-42.  
20 Shorter 
 
 
 
Moher, D., Schulz, K. F., & Altman, D. G. (2001). The CONSORT statement: revised 
recommendations for improving the quality of reports of parallel-group randomised 
trials. The Lancet, 357(9263), 1191-1194.  
Mokkink, L. B., Prinsen, C. A., Bouter, L. M., de Vet, H. C., & Terwee, C. B. (2016). The 
COnsensus-based Standards for the selection of health Measurement INstruments 
(COSMIN) and how to select an outcome measurement instrument. Brazilian journal 
of physical therapy, 20(2), 105-113. 
National Institute for Health and Clinical Excellence. (2010). NICE  Public  Health  (PH)  
Guideline  24: Alcohol  use  disorders – preventing  harmful  drinking. Retrieved from 
http://www.nice.org.uk/PH24 
Prinsen, C. A., Vohra, S., Rose, M. R., Boers, M., Tugwell, P., Clarke, M., . . . Terwee, C. B. 
(2016). How to select outcome measurement instruments for outcomes included in a 
"Core Outcome Set" - a practical guideline. Trials, 17(1), 449. 
Schmitt, J., Langan, S., Stamm, T., & Williams, H. C. (2011). Core outcome domains for 
controlled trials and clinical recordkeeping in eczema: international multiperspective 
Delphi consensus process. J Invest Dermatol, 131(3), 623-630.  
Shorter, G. W., Newbury- Birch, D., Heather, N., Giles, E. L., Holloway, A., Bray, J. W., . . . 
O'Donnell, A. J. (2016). Systematic review to identify and appraise outcome measures 
and domains used in trials evaluating alcohol screening and brief interventions: the 
Outcome Reporting in Brief Intervention Trials (ORBIT) project review. Retrieved 
from https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=47185  
Shorter, G. W., Heather, N., Bray, J. W., Giles, E. L., Holloway, A., Barbosa, C., . . . 
Newbury-Birch, D. (2017). The ‘Outcome Reporting in Brief Intervention Trials: 
Alcohol’ (ORBITAL) framework: protocol to determine a core outcome set for 
21 Shorter 
 
 
 
efficacy and effectiveness trials of alcohol screening and brief intervention. Trials, 
18(1), 611.  
Shorter, G. W., Bray, J. W., Giles, E. L., Heather, N., Berman, A. H., O’Donnell, A. J., 
Holloway, A., Barbosa, C., Scott, S. J., Stockdale, K. J., Clarke, M., Newbury-Birch, 
D. (Under review). The variability of outcomes used in efficacy and effectiveness 
trials of alcohol brief interventions: A systematic review. Addiction. 
Sinha, I., Smyth, R., & Williamson, P. (2011). Using the Delphi technique to determine 
which outcomes to measure in clinical trials: recommendations for the future based on 
a systematic review of existing studies. PLoS Med, 8(1), e1000393.  
White, A., Kavanagh, D., Stallman, H., Klein, B., Kay-Lambkin, F., Proudfoot, J., . . . 
Young, R. (2010). Online Alcohol Interventions: A Systematic Review. Journal of 
Medical Internet Research, 12(5), e62. doi:10.2196/jmir.1479 
Williamson, P. R., Altman, D. G., Bagley, H., Barnes, K. L., Blazeby, J. M., Brookes, S. T., . 
. . Young, B. (2017). The COMET Handbook: version 1.0. Trials, 18(Suppl 3), 280. 
doi:10.1186/s13063-017-1978-4 
Williamson, P. R., Altman, D. G., Blazeby, J., Clarke, M., & Gargon, E. (2012). Driving up 
the quality and relevance of research through the use of agreed core outcomes. 
Journal of health services research & policy, 17(1), 1-2.  
Williamson, P. R., & Clarke, M. (2012). The COMET (Core Outcome Measures in 
Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews. Cochrane 
Database Syst Rev(5), ED000041.  
 
22 Shorter 
 
 
 
Tables 
Table 1: Characteristics of registrants, and the participants in e-Delphi survey rounds 1 and 2 
 Registrants 
n=150 
Round 1 
N=137 
Round 2 
N=114 
Stakeholder group    
Researchers 91 (60.7%) 87 (63.5%) 72 (63.2%) 
Healthcare and other professionals (including policy makers) 50 (33.3%) 42 (30.7%) 34 (29.8%) 
Patient/Public involvement panel 9 (6.0%) 8 (5.8%) 8 (7.0%) 
Gender    
Male 63 (42.0%) 61 (44.5%) 49 (43.0%) 
Female 85 (56.7%) 75 (54.7%) 64 (56.1%) 
Trans* 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Rather not say 1 (0.7%) 0 (0.0%) 0 (0.0%) 
Country    
Argentina 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Australia 3 (2.0%) 3 (2.2%) 3 (2.6%) 
Brazil 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Canada 2 (1.3%) 2 (1.5%) 2 (1.8%) 
Denmark 1 (0.7%) 1 (0.7%) 1 (0.9%) 
France 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Germany 3 (2.0%) 2 (1.5%) 2 (1.8%) 
Ireland 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Italy 2 (1.3%) 2 (1.5%) 1 (0.9%) 
Mexico 1 (0.7%) 0 (0.0%) 0 (0.0%) 
Netherlands 4 (2.7%) 4 (2.9%) 2 (1.8%) 
Other (not specified) 3 (2.0%) 3 (2.2%) 3 (2.7%) 
Portugal 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Spain 1 (0.7%) 1 (0.7%) 1 (0.9%) 
Sweden 3 (2.0%) 3 (2.2%) 2 (1.8%) 
Switzerland 7 (4.7%) 7 (5.1%) 6 (5.3%) 
Thailand 2 (1.3%) 2 (1.5%) 1 (0.9%) 
Uganda 1 (0.7%) 1 (0.7%) 1 (0.9%) 
United Kingdom 68 (45.3%) 59 (43.1%) 48 (42.1%) 
United States of America 44 (29.3%) 42 (30.7%) 36 (31.6%) 
#  alcohol brief intervention trials you have been involved in 
0 45 (29.3%) 37 (27.0%) 30 (26.3%) 
1 22 (14.7%) 18 (13.1%) 15 (13.2%) 
2 30 (20.0%) 30 (21.9%) 27 (23.7%) 
3 15 (10.0%) 14 (10.2%) 12 (10.5%) 
4+ 39 (26.0%) 38 (27.7%) 30 (26.3%) 
# systematic reviews which include alcohol brief intervention trials you have been involved in 
0 89 (59.3%) 80 (58.4%) 67 (58.8%) 
1 26 (17.23) 23 (16.8%) 20 (17.5%) 
2 18 (12.0%) 17 (12.4%) 16 (14.0%) 
3 9 (6.0%) 9 (6.6%) 7 (6.1%) 
4+ 8 (5.3%) 8 (5.8%) 4 (3.5%) 
# measurement instruments developed which could be used as an outcome in an alcohol brief 
intervention trial 
0 92 (60.7%) 82 (59.9%) 67 (58.8%) 
1 34 (22.7%) 30 (21.9%) 26 (22.8%) 
23 Shorter 
 
 
 
2 12 (8.0%) 12 (8.8%) 10 (8.8%) 
3 6 (4.0%) 6 (4.4%) 5 (4.4%) 
4+ 7 (4.7%) 7 (5.1%) 6 (5.3%) 
# core outcome sets you have been involved in developing (including as a Delphi participant) 
0 107 (71.3%) 97 (70.8%) 83 (72.8%) 
1 20 (13.3%) 20 (14.6%) 16 (14.0%) 
2 9 (6.0%) 8 (5.8%) 5 (4.4%) 
3 3 (2.0%) 3 (2.2%) 3 (2.6%) 
4+ 11 (7.3%) 9 (6.6%) 7 (6.1%) 
In which setting do you have alcohol brief intervention experience 
Alcohol or Drug Treatment 57 (38.0%) 51 (37.2%) 42 (36.8%) 
Criminal Justice (Prison, Probation, or other setting) 22 (14.7%) 21 (15.3%) 17 (14.9%) 
Emergency care (e.g. Trauma Center, Emergency Room) 47 (31.3%) 45 (32.8%) 35 (30.7%) 
Inpatient hospital care (not alcohol/drug treatment/emergency 
care) 
50 (33.3%) 47 (34.3%) 37 (32.5%) 
Outpatient hospital care (e.g. sexual health clinic) 50 (33.3%) 46 (33.6%) 37 (32.5%) 
Mobile based brief interventions 28 (18.7%) 27 (19.7%) 23 (20.2%) 
Online web based brief interventions 42 (28.0%) 40 (29.2%) 35 (30.7%) 
Pharmacy or Drug Store brief interventions 8 (5.3%) 8 (5.8%) 4 (3.5%) 
Primary Care (General Practice or Family Physician) 55 (36.7%) 52 (38.0%) 42 (36.8%) 
Schools 21 (14.0%) 20 (14.6%) 16 (14.0%) 
Universities and Colleges 43 (28.7%) 41 (29.9%) 33 (28.9%) 
Veterans/military 2 (1.3%) 2 (1.5%) 2 (1.8%) 
Workplaces (includes employee assistance programs/job centers) 24 (16.0%) 22 (16.1%) 14 (12.3%) 
Licensed Premises 5 (3.3%) 5 (3.6%) 1 (0.9%) 
General Population, community, or convenience samples 8 (5.3%) 8 (5.8%) 7 (6.1%) 
Social Services 2 (1.3%) 2 (1.5%) 1 (0.9%) 
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Table 2: Consumption domain rankings from e-Delphi questionnaires in Rounds 1 and 2 
 Round 1 Round 2 
N Scored 
1-3 
n (%) 
Scored 
4-6 
n (%) 
Scored 
7-9 
n (%) 
n Scored 
1-3 
n (%) 
Scored 
4-6 
n (%) 
Scored 
7-9 
n (%) 
Consumption          
How often (frequency) a person drinks heavily or large number of drinks on occasion 136 3 (2.2%) 20 (14.7%) 113(83.1%) 105 1 (1.0%) 6 (5.7%) 98 (93.3%) 
Total number of standard drinks consumed in a week 136 2 (1.5%) 28 (20.6%) 106(77.9%) 107 2 (1.9%) 8 (7.5%) 97 (90.7%) 
How often (frequency) a person drinks alcohol 136 3 (2.2%) 32 (23.5%) 101(74.3%) 105 2 (1.9%) 12 (11.4%) 91 (86.7%) 
Drinking at a level which puts you at risk of harm (hazardous or harmful drinking) 136 4 (2.9%) 39 (28.7%) 93 (68.4%) 104 1 (1.0%) 18 (17.3%) 85 (81.7%) 
Alcohol related problems or consequences due to alcohol use 134 2 (1.5%) 28 (20.9%) 108(80.6%) 113 0 (0.0%) 21 (18.6%) 92 (81.4%) 
Combined consumption measure which takes into consideration one or more 
consumption measures together (e.g. frequency, quantity, or frequency of heavy 
drinking together in one measure) 
136 6 (4.4%) 38 (27.9%) 92 (67.6%) 104 4 (3.8%) 16 (15.4%) 84 (80.8%) 
Typical number of drinks consumed in a drinking occasion 136 5 (3.7%) 55 (40.4%) 76 (55.9%) 102 2 (1.9%) 28 (27.2%) 73 (70.9%) 
Abuse symptomatology (severity of the symptoms of alcohol abuse; excessive use) 135 10 (7.4%) 80 (59.3%) 65 (48.1%) 109 5 (4.6%) 49 (45.0%) 55 (50.5%) 
Days abstinent: number of days in a period of time in which a person does not 
drink/abstains from alcohol 133 15 (11.3%) 64 (48.1%) 54 (40.6%) 108 12 (11.1%) 51 (47.2%) 45 (41.7%) 
Dependence symptomatology (Severity of the symptoms of alcohol dependence; 
physical or psychological need to drink alcohol) 134 16 (11.9%) 102(76.1%) 48 (35.8%) 109 6 (5.5%) 65 (59.6%) 38 (34.9%) 
Drinking above the government guidelines for low risk drinking in a given country 136 24 (17.6%) 61 (44.9%) 51 (37.5%) 102 18 (17.6%) 51 (50.0%) 33 (32.4%) 
Number of drinks consumed in a month or other period 136 31 (22.8%) 63 (46.3%) 42 (30.9%) 104 23 (22.1%) 51 (49.0%) 30 (28.8%) 
Largest number of drinks on occasion 133 21 (15.8%) 69 (51.9%) 43 (31.6%) 104 7 (6.7%) 68 (65.4%) 29 (27.9%) 
The use of alcohol with another drug (e.g. tobacco or an illegal drug) at the same time 
or in the same time period 135 24 (17.8%) 76 (56.3%) 35 (25.9%) 104 15 (14.4%) 62 (61.4%) 26 (23.8%) 
How often (frequency) a person drinks enough to feel drunk/intoxicated 136 22 (16.2%) 67 (49.3%) 47 (34.6%) 104 16 (15.4%) 67 (64.4%) 21 (20.2%) 
Drinks consumed in the heaviest week of drinking in a given time period 136 18 (13.2%) 79 (58.1%) 39 (28.7%) 104 12 (11.5%) 76 (73.1%) 16 (15.4%) 
Blood Alcohol Consumption (Levels of alcohol in the blood; may be measured using 
a breathalyzer; or calculated based on reports of alcohol consumption) 136 53 (39.0%) 60 (44.1%) 23 (16.9%) 108 42 (38.9%) 53 (49.1%) 13 (12.0%) 
Matching goals set before drinking about how much alcohol you plan to drink or how 
long you plan to drink for 134 39 (29.1%) 71 (53.0%) 24 (17.9%) 104 23 (22.1%) 73 (70.2%) 8 (7.7%) 
The time spent drinking alcohol 136 51 (37.5%) 68 (50.0%) 17 (12.5%) 103 50 (48.5%) 49 (47.6%) 4 (3.9%) 
The type of drink consumed 136 68 (50.0%) 53 (39.0%) 15 (11.0%) 102 67 (65.7%) 31 (30.4%) 4 (3.9%) 
If your drinking matches the report of someone who was there at the same time 135 73 (54.1%) 59 (43.7%) 3 (2.2%) 104 74 (71.2%) 29 (27.9%) 1 (1.0%) 
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How much alcohol a family member or partner drinks; or other people who are similar 
to the participant 135 73 (54.1%) 53 (39.3%) 9 (6.7%) 104 67 (64.4%) 37 (35.6%) 0 (0.0%) 
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Table 3: Rankings from e-Delphi rounds 1 and 2 in the biomarkers, economic factors/resource use, health, psychological factors, intervention 
factors, and life impact domains 
 Round 1 Round 2 
n Scored 
1-3 
N (%) 
Scored 
4-6 
N (%) 
Scored 
7-9 
N (%) 
N Scored 
1-3 
N (%) 
Scored 
4-6 
N (%) 
Scored 
7-9 
N (%) 
Biomarkers          
Phosphatidylethanol (PETH) suggested by three individuals and scored 8; 7; and 4 N/A – not included in Round 1 76 20 (26.3%) 39 (51.3%) 17 (22.4%) 
Alanine aminotransferase  91 25 (27.5%) 51 (56.0%) 15 (16.5%) 81 20 (24.7%) 48 (59.3%) 13 (16.0%) 
Gamma-glutamyltransferase  93 28 (30.1%) 48 (51.6%) 17 (18.3%) 79 23 (29.1%) 44 (55.7%) 12 (15.2%) 
Analyzing hair for ethyl-glucuronide suggested by two participants scoring 4, and 7. N/A – not included in Round 1 79 32 (40.5%) 37 (46.8%) 10 (12.7%) 
Aspartate aminotransferase  89 26 (29.2%) 52 (58.4%) 11 (12.4%) 78 23 (29.5%) 46 (59.0%) 9 (11.5%) 
Mean corpuscular volume (MCV)  92 34 (37.0%) 46 (50.0%) 12 (13.0%) 78 30 (38.5%) 40 (51.3%) 8 (10.3%) 
Levels of whole blood-associated acetaldehyde suggested by one participant and scored 6 N/A – not included in Round 1 74 24 (32.4%) 43 (58.1%) 7 (9.5%) 
Carbohydrate-deficient transferrin 92 25 (27.2%) 48 (52.2%) 19 (20.7%) 79  20 (25.3%) 44 (55.7%) 15 (9.0%) 
Economic Factors/Resource Use         
Alcohol related injury (physical injury as a result of alcohol use) 130 3 (2.3%) 44 (33.8%) 83 (63.8%) 102 5 (4.9%) 26 (25.5%) 71 (69.6%) 
Use of drug/alcohol treatment in a healthcare setting or by a healthcare professional 130 11 (8.5%) 49 (37.7%) 70 (53.8%) 102 6 (5.9%) 32 (31.4%) 64 (62.7%) 
Use of emergency healthcare services 130 12 (9.2%) 48 (36.9%) 70 (53.8%) 102 6 (5.9%) 34 (33.3%) 62 (60.8%) 
Hospitalizations (inpatient healthcare services in a ward other than the emergency room) 129 8 (6.2%) 51 (39.5%) 70 (54.3%) 101 5 (5.0%) 35 (34.7%) 61 (60.4%) 
Alcohol related driving offences/impaired driving (including drink driving or accidents) 131 9 (6.9%) 48 (36.6%) 74 (56.5%) 102 6 (5.9%) 40 (39.2%) 56 (54.9%) 
Use of primary healthcare services (e.g. general practice/primary care/family physician) 130 15 (11.5%) 55 (42.3%) 60 (46.2%) 102 10 (9.8%) 37 (36.3%) 55 (53.9%) 
Seeking help for alcohol or drugs not from a healthcare provider 128 19 (14.8%) 61 (47.7%) 48 (37.5%) 100 10 (10.0%) 44 (44.0%) 46 (46.0%) 
General healthcare use (an overall measure of the use of healthcare services) 130 20 (15.4%) 63 (48.5%) 47 (36.2%) 101 9 (8.9%) 50 (49.5%) 42 (41.6%) 
Alcohol related offences (may relate to the setting e.g. alcohol related violence or 
university rule violations) 
131 10 (7.6%) 71 (54.2%) 50 (38.2%) 102 8 (7.8%) 56 (54.9%) 38 (37.3%) 
General accident costs (not just alcohol related accidents) 129 31 (24.0%) 55 (43.4%) 42 (32.6%) 101 25 (24.8%) 53 (52.5%) 23 (22.8%) 
General criminal justice costs (not those directly related to an alcohol offence) 129 36 (27.9%) 56 (43.4%) 38 (29.0%) 101 30 (29.7%) 50 (49.5%) 21 (20.8%) 
Prescribed medication use (medication with a prescription from a Doctor) 129 34 (26.4%) 63 (48.8%) 32 (24.8%) 100 22 (22.0%) 59 (59.0%) 19 (19.0%) 
Social service use (e.g. child protection; government sponsored unemployment support) 126 21 (16.7%) 76 (60.3%) 29 (23.0%) 100 21 (21.0%) 60 (60.0%) 19 (19.0%) 
Use of pharmacies or drug store advice 129 46 (35.7%) 65 (50.4%) 18 (14.0%) 99 42 (42.4%) 50 (50.5%) 7 (7.1%) 
Over the counter medication use 126 49 (38.9%) 64 (50.8%) 13 (10.3%) 99 39 (39.4%) 55 (55.6%) 5 (5.1%) 
Life impact         
Quality of life (the standard of health/comfort/happiness experienced by an individual) 131 6 (4.6%) 42 (32.1%) 83 (63.4%) 102 2 (2.0%) 19 (18.6%) 81 (79.4%) 
Alcohol causing harm to other people - recommended by one participant and scored 7 N/A – not included in Round 1 101 10 (9.9%) 55 (54.5%) 36 (35.6%) 
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Workplace or college/university productivity (such as the ability to work; or ability to 
meet deadlines or targets) 
131 21 (16.0%) 72 (55.0%) 38 (29.0%) 102 14 (13.7%) 66 (64.7%) 22 (21.6%) 
Ability to participate in society; or quality of relationships (e.g. within a family) 131 16 (12.2%) 74 (56.5%) 41 (31.3%) 102 8 (7.8%) 73 (71.6%) 21 (20.6%) 
Satisfaction with social roles and activities 131 18 (13.7%) 76 (58.0%) 37 (28.2%) 102 13 (12.7%) 75 (73.5%) 14 (13.7%) 
Improvement in finances (money available to spend on other things)- suggested by one 
participant and scored 6 
N/A – not included in Round 1 102 28 (27.5%) 68 (66.7%) 6 (5.9%) 
Health         
Psychological/mental health (unpleasant feelings which impact ability to live life) 131 4 (3.1%) 52 (39.7%) 76 (55.9%) 102 5 (4.9%) 31 (30.4%) 66 (64.7%) 
Overall health or how healthy the person feels 131 7 (5.3%) 60 (45.8%) 64 (48.9%) 102 4 (3.9%) 44 (43.1%) 54 (52.9%) 
Risk of alcohol withdrawal symptoms (like delirium tremens) 126 21 (16.7%) 70 (55.1%) 35 (27.8%) 100 13 (13.0%) 43 (43.0%) 44 (44.0%) 
Mortality or death related to alcohol use - Recommended by one person and scored 8 N/A – not included in Round 1 93 18 (19.4%) 35 (37.6%) 40 (43.0%) 
Physical health (ability to carry out physical activities from basic self-care to running) 130  10 (7.7%) 63 (48.5%) 57 (43.8%) 102 7 (6.9%) 57 (55.9%) 38 (37.3%) 
Severity of the symptoms of depression or low mood 130 8 (6.2%) 64 (49.2%) 58 (44.6%) 102 6 (5.5%) 51 (59.6%) 38 (34.9%) 
Suicidal ideas or beliefs 129 20 (15.5%) 72 (55.8%) 37 (28.7%) 101 15 (14.9%) 62 (61.4%) 24 (23.8%) 
Severity of the symptoms of anxiety (feeling worried) 130 16 (12.3%) 73 (56.2%) 41 (31.5%) 102 13 (12.7%) 71 (69.6%) 8 (17.6%) 
How often a person experiences a hangover (a range of unpleasant symptoms 
experienced after drinking alcohol which may include tiredness; thirst; nausea or 
vomiting; trouble sleeping; low mood; headache; anxiety or other aspects) 
129 30 (23.3%) 75 (58.1%) 24 (18.6%) 102 19 (18.6%) 66 (64.7%) 17 (16.7%) 
Problems sleeping (either too much or too little) 130 26 (20.0%) 77 (59.2%) 27 (20.8%) 101 21 (20.8%) 65 (64.4%) 15 (14.9%) 
Number of medical conditions someone has (as diagnosed by a doctor) 129 29 (22.5%) 75 (58.1%) 25 (19.4%) 102 24 (23.5%) 64 (62.7%) 14 (13.7%) 
Factors relating to heart health (such as blood pressure) 129 33 (25.6%) 73 (56.6%) 23 (17.8%) 101 29 (28.7%) 62 (61.4%) 10 (9.9%) 
Factors relating to obesity (such as body mass index; body fat percentage) 129 34 (26.4%) 76 (58.9%) 19 (14.7%) 101 29 (28.7%) 66 (65.3%) 10 (9.9%) 
Post-traumatic stress disorder symptoms (anxiety caused by events including upsetting 
memories; or sleep problems; or avoiding reminders of the event) 
129 37 (28.7%) 74 (57.4%) 18 (14.0%) 102 28 (27.7%) 63 (62.4%) 10 (9.9%) 
Quality of working partnership with healthcare provider 129 45 (34.9%) 63 (48.8%) 21 (16.3%) 101 34 (33.7%) 58 (57.4%) 9 (8.9%) 
Problems with stomach or digestion (including abdominal 
pain/swelling/vomiting/nausea) 
129 32 (24.8%) 78 (60.5%) 19 (14.7%) 101 28 (27.7%) 64 (63.4%) 9 (8.9%) 
Problems with sex life 129 32 (24.8%) 83 (64.3%) 14 (10.9%) 101 33 (32.7%) 62 (61.4%) 6 (5.9%) 
Psychological Factors         
Interest in making changes around alcohol use (motivation/readiness to change) 131 8 (6.1%) 51 (38.9%) 72 (55.0%) 102 2 (2.0%) 27 (26.5%) 73 (71.6%) 
If alcohol is used to cope with stress; anxiety; or life events 130 12 (9.2%) 63 (48.5%) 55 (42.3%) 101 7 (6.9%) 50 (49.5%) 44 (43.6%) 
If the participant believes their alcohol use affects their health 130 13 (10.0%) 61 (46.9%) 56 (43.1%) 102 13 (12.7%) 46 (45.1%) 43 (42.2%) 
Engaging in protective behavioral strategies  128 6 (4.7%) 70 (54.7%) 52 (40.6%) 101 12 (11.9%) 49 (48.5%) 40 (39.6%) 
Cravings or a powerful desire for alcohol 130 22 (16.9%) 55 (42.3%) 53 (40.8%) 102 11 (10.8%) 51 (50.0%) 40 (39.2%) 
Self-efficacy or belief in ability to succeed/achieve goals 131 15 (11.5%) 57 (43.5%) 59 (45.0%) 102 9 (8.8%) 55 (53.9%) 38 (37.3%) 
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Ability to refuse alcohol (sometimes called drinking refusal self-efficacy or how able 
someone is to refuse alcohol in places it may be usually consumed) 
130 19 (14.6%) 57 (43.8%) 54 (41.5%) 102 8 (7.8%) 59 (57.8%) 35 (34.3%) 
Outcome expectancies; the belief that drinking leads to specific positive or negative 
outcomes or what a person expects to happen as a result of a given action 
129 5 (3.9%) 61 (46.6%) 97 (75.2%) 102 14 (13.7%) 56 (54.9%) 32 (31.4%) 
Alcohol's effect on the ability to reach goals (called goal striving) 129 21 (16.3%) 73 (56.6%) 35 (27.1%) 101 14 (13.9%) 58 (57.4%) 29 (28.7%) 
Engaging in other risky behaviors (e.g. putting yourself in a dangerous place/situation) 130 22 (16.9%) 71 (54.6%) 37 (28.5%) 101 15 (14.9%) 62 (61.4%) 24 (23.8%) 
Attitudes to alcohol consumption in pregnancy 130 24 (18.5%) 56 (43.1%) 50 (38.5%) 101 21 (20.8%) 57 (56.4%) 23 (22.8%) 
Feeling supported (perhaps by family and friends) 130 31 (23.8%) 67 (51.5%) 32 (24.6%) 101 24 (23.8%) 60 (59.4%) 17 (16.8%) 
How confident an individual feels/their self esteem 131 20 (15.3%) 71 (54.2%) 40 (30.5%) 102 17 (16.7%) 68 (66.7%) 17 (16.7%) 
How positively or negatively alcohol is viewed by the participant 131 19 (14.5%) 78 (59.5%) 34 (26.0%) 102 16 (15.7%) 70 (68.6%) 16 (15.7%) 
Empathy (ability to understand and share feelings of another) 126 54 (42.9%) 59 (46.8%) 13 (10.3%) 100 60 (60.0%) 35 (35.0%) 15 (15.0%) 
Engaging in healthy behaviors such as exercise or healthy eating 130 17 (13.1%) 76 (58.5%) 37 (28.5%) 102 14 (13.7%) 74 (72.5%) 14 (13.7%) 
How stressed out someone feels 130 23 (17.7%) 84 (64.6%) 23 (17.7%) 102 18 (17.6%) 70 (68.6%) 14 (13.7%) 
Feeling alone or isolated 130 34 (26.2%) 70 (53.8%) 26 (20.0%) 101 27 (26.7%) 64 (63.4%) 10 (9.9%) 
Aggression or anger (either feelings or actions) 130 28 (21.5%) 80 (61.5%) 22 (16.9%) 102 23 (22.5%) 69 (67.6%) 10 (9.8%) 
Acting impulsively (acting without thinking/considering longer-term costs & benefits) 131 38 (29.0%) 78 (59.5%) 15 (11.5%) 102 44 (43.1%) 55 (53.9%) 3 (2.9%) 
How positively other people's alcohol use is viewed 130 39 (30.2%) 75 (57.7%) 16 (12.3%) 102 39 (38.2%) 61 (59.8%) 2 (2.0%) 
Seeking new and exciting experiences (interest in experiences which are new/exciting) 131 47 (35.9%) 74 (56.5%) 10 (7.6%) 102 59 (57.8%) 41 (40.2%) 2 (2.0%) 
How stressed out someone feels 130 23 (17.7%) 84 (64.6%) 23 (17.7%) 102 18 (17.6%) 70 (68.6%) 14 (13.7%) 
Intervention factors         
If the intervention was delivered as planned; or the participant used the intervention. 129 5 (3.9%) 27 (20.9%) 97 (75.2%) 102 4 (3.9%) 15 (14.7%) 83 (81.4%) 
Satisfaction with intervention (the view of intervention from the person taking part) 131 2 (1.5%) 61 (46.6%) 68 (51.9%) 102 2 (2.0%) 41 (40.2%) 59 (57.8%) 
Clinician satisfaction with intervention: suggested by one participant, rated 7 N/A – not included in Round 1 102 19 (18.6%) 65 (63.7%) 18 (17.6%) 
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Supplementary Material A: Additional outcomes suggested for Round 2 questionnaire with explanation of whether outcome added, covered by 
existing item, or not relevant 
 
Suggested outcome with 
ranking in brackets 
Matched existing Round 1 
outcome if relevant  
New outcome if relevant (with descriptor) Narrative 
Those added to the Round 2 questionnaire 
Mortality (8)  Mortality or Death Not currently present 
PETh (8)  Levels of Phosphatidylethanol in the blood 
(Phosphatidylethanol can be detected in the 
blood for up to three weeks and can indicate 
regular drinking, or heavy drinking.) 
Not currently present 
PETh (4)  
EtG - Ethyl glucuronide on 
head hair (7) 
 Analyzing hair for ethyl-glucuronide (ethyl-
glucuronide is present in hair up to 3/4 days 
after alcohol is consumed- it shows if someone 
has had an alcoholic drink recently) 
Not currently present 
Biomarkers: Hair analysis for 
ethyl-glucuronide(4) 
 
Clinician Satisfaction (7) 
 
 Clinician satisfaction (Clinician satisfaction with 
the alcohol brief intervention) 
Not currently present 
broader measures of harm to 
others e.g. domestic violence 
for economic outcomes (7) 
 Alcohol causing harm to other people often 
called ‘harm to others’ (The general impact that 
a person’s alcohol has on other people than the 
drinker) 
This was partially covered by other 
issues (such as alcohol related 
offences, or role and relationship 
factors but was considered a distinct 
composite outcome) 
Improved social aspects – 
finance (6) 
 Improvement in finances (Changes in the 
amount of money a person has (either more or 
less) as a result of change in how much is being 
spent on alcohol) 
Not currently present 
WBAA (6)  Levels of whole blood-associated acetaldehyde 
(whole blood-associated acetaldehyde tests can 
detect heavy alcohol consumption through the 
presence of acetaldehyde (a by-product of 
alcohol consumption) for up to three weeks 
following use) 
Not currently present 
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Suggested outcomes covered by existing outcomes 
Concomitant use of Tobacco; 
Marijuana; Other Drug (8) 
The use of alcohol with 
another drug 
 Was covered by existing outcome 
Self-reported general health (8) Overall health  Was covered by existing outcome 
Patient adherence to the BI (8) If the intervention was 
delivered as planned, or if 
the participant used the 
intervention 
 Was covered by existing outcome 
Followed-up by 
attending/seeking further 
professional help. (7) 
Use of drug or alcohol 
treatment services provided 
in a healthcare setting or by 
a healthcare professional 
 Was covered by existing outcome; 
timing is a measurement issue to be 
covered by guidance on how to 
measure an outcome if selected for 
core outcome set 
Likelihood of seeking to change 
alcohol use in the future (6) 
Interest in making changes 
around alcohol use 
 Was covered by existing outcome; 
timing is a measurement issue to be 
covered by guidance on how to 
measure an outcome if selected for 
core outcome set 
Other sources of help (current) 
(6) 
Seeking help for alcohol or 
drugs not from a healthcare 
provider 
 Was covered by existing outcome; 
timing is a measurement issue to be 
covered by guidance on how to 
measure an outcome if selected for 
core outcome set 
Improved social aspects - 
employability or education 
(general) (6) 
Workplace or college 
productivity 
 Was covered by existing outcome 
Number of arrests (6); General criminal justice 
costs 
 Was covered by existing outcome 
Number of nights incarcerated 
(6) 
General criminal justice 
costs 
 Was covered by existing outcome 
Number of court appearances 
(6) 
General criminal justice 
costs 
 Was covered by existing outcome 
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Number of days on community 
supervision (probation/parole) 
(societal cost driver/distinct 
from other criminal justice 
outcomes)(6) 
General criminal justice 
costs 
 Was covered by existing outcome 
How the person evaluates the 
impact of alcohol in their life 
(5) 
Alcohol's effect on the 
ability to reach life goals 
 Was covered by existing outcome 
Previous / history use of alcohol 
treatment services (5)  
 
Use of drug or alcohol 
treatment services provided 
in a healthcare setting or by 
a healthcare professional 
 Was covered by existing outcome 
DSM-V criteria (5) Dependence/abuse 
symptomatology  
 As the core outcome set is directed to 
non-treatment seekers, this is partially 
covered by other outcomes but may 
not be relevant to the population 
Not included in the questionnaire at Round 2 
Clinician decision to consider 
alcohol use in treatment of 
existing medical conditions. (6) 
  Not an indicator of BI effectiveness or 
efficacy 
Clinician decision to consider 
alcohol use in prescribing 
medications. (6) 
  Not an indicator of BI effectiveness or 
efficacy 
Number of brief interventions 
offered in the past (5) 
  Not an indicator of BI effectiveness or 
efficacy 
Setting in which the brief 
intervention was offered (6) 
  Not an indicator of BI effectiveness or 
efficacy 
Was the brief intervention 
facilitated or un-facilitated (6) 
  Not an indicator of BI effectiveness or 
efficacy 
Was it an blended intervention 
(mix of face to face and on line) 
(6) 
  Not an indicator of BI effectiveness or 
efficacy 
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Improvement in housing (6)   Unsure of relevance to ABI studies, 
and was ranked below 7-9 “critical for 
inclusion” cut off. 
 
